Friday, December 01, 2017 12:28:06 PM
The Inability For Placebo to Change Alzheimer’s Remains
Yes, as the quoted text relates, analgesics (for pain reduction, as in migraine) and similar drugs are open to the placebo effect. No question about that.
The fact remains, however, there are no demonstrated or recorded cases of any “drug” (sham pill) ever causing the strong, persisting cognition stabilization or improvements that Anavex 2-73 did in the Australian trial. There is no conceivable mechanism by which the placebo effect, patient expectation (that’s the key factor), could possibly remove beta-amyloid plaques or tau tangles recognizably causing Alzheimer’s symptoms. The unique mechanisms of action of Anavex 2-73 could do this, however.
When will some drug be reported that it heals new broken bones after a 5-day course of treatment? Impossible. With broken bones, there can be no authentic placebo effect, where patient expectation “causes” the severed bones to quickly and spontaneously re-connect. Physically and chemically impossible.
The same is true with Alzheimer’s. No placebo-induced functioning of brain circuits (thinking) can possibly cause the disappearance Alzheimer’s toxins, the chemicals that actually induce all of the disease’s symptoms.
Were there existing, recognized cases of placebo effect outcomes in Alzheimer’s, the question would remain. But, for clearly obviating physiochemical reasons, mental expectations simply cannot suppress the lethal progression of Alzheimer’s disease.
One can’t wilfully believe away broken bones, hardened arteries, dental caries, urinary tract infections, cataracts, hernias, kidney stones, varicose veins, or a host of other humans diseases and conditions. Same with Alzheimer’s and Rett.
It is important to understand the placebo effect, and how it can distort or misrepresent clinical results. But it is a factor only in the conditions and diseases where it can operate. It simply can’t (and hasn’t) in Alzheimer’s or Rett.
The placebo effect is by no means operable in every human health condition.
Yes, as the quoted text relates, analgesics (for pain reduction, as in migraine) and similar drugs are open to the placebo effect. No question about that.
The fact remains, however, there are no demonstrated or recorded cases of any “drug” (sham pill) ever causing the strong, persisting cognition stabilization or improvements that Anavex 2-73 did in the Australian trial. There is no conceivable mechanism by which the placebo effect, patient expectation (that’s the key factor), could possibly remove beta-amyloid plaques or tau tangles recognizably causing Alzheimer’s symptoms. The unique mechanisms of action of Anavex 2-73 could do this, however.
When will some drug be reported that it heals new broken bones after a 5-day course of treatment? Impossible. With broken bones, there can be no authentic placebo effect, where patient expectation “causes” the severed bones to quickly and spontaneously re-connect. Physically and chemically impossible.
The same is true with Alzheimer’s. No placebo-induced functioning of brain circuits (thinking) can possibly cause the disappearance Alzheimer’s toxins, the chemicals that actually induce all of the disease’s symptoms.
Were there existing, recognized cases of placebo effect outcomes in Alzheimer’s, the question would remain. But, for clearly obviating physiochemical reasons, mental expectations simply cannot suppress the lethal progression of Alzheimer’s disease.
One can’t wilfully believe away broken bones, hardened arteries, dental caries, urinary tract infections, cataracts, hernias, kidney stones, varicose veins, or a host of other humans diseases and conditions. Same with Alzheimer’s and Rett.
It is important to understand the placebo effect, and how it can distort or misrepresent clinical results. But it is a factor only in the conditions and diseases where it can operate. It simply can’t (and hasn’t) in Alzheimer’s or Rett.
The placebo effect is by no means operable in every human health condition.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
